Romsa Jonathan, Imhoff Ryan J, Palli Swetha R, Inculet Richard, Mehta Sanjay
Department of Medical Imaging, Division of Nuclear Medicine, University of Western Ontario, 800 Commissioners Rd E, London, ON N6A 5W9, Canada.
CTI Clinical Trial & Consulting Services, 100 E. RiverCenter Blvd, Covington, KY 41011, USA.
J Comp Eff Res. 2022 Mar;11(4):229-241. doi: 10.2217/cer-2021-0139. Epub 2022 Jan 10.
SPECT/CT has been found to improve predicted postoperative forced expiratory volume in one second (ppoFEV) assessments in patients with non-small-cell lung cancer (NSCLC). An economic simulation was developed comparing the cost-effectiveness of SPECT/CT versus planar scintigraphy for a US payer. Clinical outcomes and cost data were obtained through review of the published literature. SPECT/CT increased the accuracy ppoFEV assessment, changing the therapeutic decision for 1.3% of nonsurgical patients to a surgical option, while 3.3% of surgical patients shifted to more aggressive procedures. SPECT/CT led to an expected cost of $4694 per life year gained, well below typical thresholds. SPECT/CT resulted in substantially improved health outcomes and was found to be highly cost-effective.
已发现单光子发射计算机断层扫描/计算机断层扫描（SPECT/CT）可改善非小细胞肺癌（NSCLC）患者术后一秒用力呼气量（ppoFEV）的预测评估。针对美国医保支付方，开展了一项经济模拟，比较SPECT/CT与平面闪烁扫描的成本效益。通过查阅已发表文献获取临床结果和成本数据。SPECT/CT提高了ppoFEV评估的准确性，使1.3%的非手术患者的治疗决策转变为手术选择，而3.3%的手术患者转向更积极的治疗方案。SPECT/CT导致每获得一个生命年的预期成本为4694美元，远低于典型阈值。SPECT/CT带来了显著改善的健康结果，且被发现具有很高的成本效益。
